medigraphic.com
SPANISH

Revista Mexicana de Cardiología

ISSN 0188-2198 (Print)
En 2019, la Revista Mexicana de Cardiología cambió a Cardiovascular and Metabolic Science

Ver Cardiovascular and Metabolic Science


  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
    • Send manuscript
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2008, Number 1

Next >>

Rev Mex Cardiol 2008; 19 (1)

A minimalist version about the arterial hypertension. Antihypertensor schemata treatment

Alcocer DBL, Parra CJZ, Hernández-y-H H
Full text How to cite this article

Language: Spanish
References: 9
Page: 3-6
PDF size: 77.07 Kb.


Key words:

No keywords

Text Extraction

No abstract


REFERENCES

  1. Mancia G, De Backer G, Doniczak A, Cifkova R, Fagard R, Germano G et al. Guidelines for the management of arterial hypertension: The Task Force for the Management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-1536.

  2. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptorblocker. N Engl J Med 2006; 354: 1685-1697.

  3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419.

  4. Blood pressure lowering treatment trialists’ collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527-1535.

  5. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553.

  6. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: Beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001; 37: 250-254.

  7. Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Remme W, Scherhaug A. Effects of metoprolol and carvedilol on preexisting and new onset diabetes in patients with chronic heart failure Data from the Carvedilol or metoprolol European Trial (COMET). Heart 2007.

  8. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, ASCOT investigators. The prevention of coronary events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:LLA). Lancet 2003; 361: 1149-1158.

  9. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Mex Cardiol. 2008;19